VOLITIONRX Business Summary

VolitionRx Ltd (VNRX) is a commercial-stage epigenetics company that generates revenue through the sale of diagnostic kits, licensing agreements, and fee-for-service research via its proprietary Nucleosomics platform. The company operates through four primary business segments: Nu.Q Vet, which provides commercially available cancer screening for dogs; Nu.Q NETs, focused on monitoring the immune system for conditions like sepsis; Nu.Q Discover, a service-based arm for pharmaceutical and academic profiling; and Nu.Q Cancer, dedicated to human clinical diagnostics and treatment monitoring. VolitionRx distinguishes itself in the liquid biopsy market by utilizing cost-effective nucleosome-based assays rather than expensive next-generation sequencing. It competes directly with industry giants such as Exact Sciences, Guardant Health, and GRAIL, positioning itself as a high-volume, low-cost alternative for early disease detection and monitoring. The leadership team is led by President and CEO Cameron Reynolds, an entrepreneurial executive with over 15 years of experience in biotech management and strategic planning. Key technical and operational guidance is provided by Chief Scientific Officer Dr. Jacob Micallef, the primary architect of the Nucleosomics technology, and Chief Operating Officer Dr. Gaetan Michel, who oversees global manufacturing and the company’s "Silver One" facility in Belgium. The executive suite is rounded out by CFO Terig Hughes, who brings a background in international finance from RELX Group. The company is governed by a board chaired by Timothy Still and includes lead independent director Guy Innes. Notable institutional backing includes significant positions held by Lagoda Investment Management, The Vanguard Group, and BlackRock, reflecting a stable base of institutional interest despite the company’s micro-cap valuation.